Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition

Inclusion Criteria: * Healthy male and female subjects. * Aged 18 - 55 years inclusive. * Non-smokers or moderate smokers (less than 10 cigarettes per day). * Able to participate, communicate well with the investigators and willing to provide written informed consent to participate in the study. * Body mass index within 18 to 25 kg/m2. * Vital signs (after 10 minutes rest) were within the following ranges: * systolic blood pressure 110 - 120 mmHg * diastolic blood pressure 70 - 80 mmHg * pulse rate 60 - 90 bpm Exclusion Criteria: * Personal/family history of allergy or hypersensitivity or contraindication to lisinopril or allied drugs. * Pregnant or lactating women. * Any major illness or clinically significant ongoing chronic medical illness in the past 90 days. * Any clinically significant abnormality of liver function test (ALT, AP, total bilirubin \>= 1.5 ULN). * Any clinically significant abnormality of renal function test (serum creatinine concentration \> 1.4 mg/dL). * Positive hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV. * Clinically significant hematology abnormalities. * Clinically significant electrocardiogram (ECG) abnormalities. * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug. * Past history of anaphylaxis or angioedema. * History of drug or alcohol abuse within 12 months prior to screening. * Participation in any clinical trial within the past 90 days. * History of any bleeding or coagulative disorders. * History of difficulty with donating blood or accessibility of veins in left or right arm. * A donation or loss of 500 mL (or more) of blood within 3 months before the study's first dosing day. * Intake of any prescription or non-prescription drugs, food supplements, or herbal medicines within 14 days of the study's first dosing day.